ETHICAL ISSUES IN INTERNATIONAL BIOMEDICAL RESEARCH: A CASEBOOK

Contributors -- Introduction / James V. Lavery, Christine Grady, Elizabeth R. Wahl, and Ezekiel J. Emanuel -- Pt. I: Collaborative partnership -- Case 1: Community involvement in biodiversity prospecting in Mexico -- Commentary 1.1: Private and public knowledge in the debate on bioprospecting: impli...

Full description

Bibliographic Details
Other Authors: Lavery, James V., Grady, Christine, Wahl, Elizabeth R., Emanuel, Ezekiel J.
Language:English
Published: 2007
Subjects:
Online Access:http://hdl.handle.net/10822/548221
Description
Summary:Contributors -- Introduction / James V. Lavery, Christine Grady, Elizabeth R. Wahl, and Ezekiel J. Emanuel -- Pt. I: Collaborative partnership -- Case 1: Community involvement in biodiversity prospecting in Mexico -- Commentary 1.1: Private and public knowledge in the debate on bioprospecting: implications for local communities and prior informed consent / Brent Berlin and Elois A. Berlin -- Commentary 1.2: Politics, risk, and community in the Maya ICBG Case / Fern Brunger and Charles Weijer -- Case 2: Selling genes -- Commentary 2.1: What might Tonga learn from Iceland? / James Till and David L. Tritchler -- Commentary 2.2: Whose DNA? Tonga and Iceland, biotech, ownership, and consent / Lopeti Senituli and Margaret Boyes -- Case 3: Sustainability of a fluoride varnish feasibility study in Nicaragua -- Commentary 3.1: Sustainability and obligations to the community in the Nicaragua fluoride varnish pilot study: the investigator's perspective / Martin Hobdell -- Commentary 3.2: Assessing the sustainability of the Nicaragua fluoride varnish study / Florencia Luna -- Pt. II: Social value -- Case 4: Malarone testing in pregnant women in Thailand -- Commentary 4.1: Proposed phase 3 trials of Malarone in pregnancy are unethical / Juntra Karbwang -- Commentary 4.2: A phase 3 trial of Malarone in pregnancy as a pubic good / Janis Lazdins -- Case 5: Neglected diseases: incentives to conduct research in developing countries -- Commentary 5.1: Drug development for visceral leishmaniasis: a failure of the market and public policy / James Orbinski and Solomon Benatar -- Commentary 5.2: Bringing innovations for diseases of poverty to market: the case of paromomycin for visceral leishmaniasis / Hannah Kettler -- Pt. III: Scientific validity -- Case 6: Evaluating home-based treatment strategies for neonatal sepsis in India -- Commentary 6.1: Did the SEARCH neonatal sepsis trial violate the Declaration of Helsinki? / Zulfiqar A. Bhutta -- Commentary 6.2: The SEARCH neonatal sepsis study: was it ethical? / Marcia Angell -- Case ...